Martin Kolb

31.0k total citations · 6 hit papers
279 papers, 14.9k citations indexed

About

Martin Kolb is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Martin Kolb has authored 279 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Pulmonary and Respiratory Medicine, 64 papers in Physiology and 31 papers in Molecular Biology. Recurrent topics in Martin Kolb's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (211 papers), Sarcoidosis and Beryllium Toxicity Research (57 papers) and Pulmonary Hypertension Research and Treatments (43 papers). Martin Kolb is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (211 papers), Sarcoidosis and Beryllium Toxicity Research (57 papers) and Pulmonary Hypertension Research and Treatments (43 papers). Martin Kolb collaborates with scholars based in Canada, United States and Germany. Martin Kolb's co-authors include Jack Gauldie, Peter J. Margetts, Kjetil Ask, Susanne Stowasser, Philippe Bonniaud, David Warburton, Antje Moeller, László Farkas, Luca Richeldi and Patricia J. Sime and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Martin Kolb

264 papers receiving 14.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

2019 1.3k citations Kevin R. Flaherty, Athol U. Wells et al. New England Journal of Medicine profile →
The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

2007 784 citations Kjetil Ask, Jack Gauldie et al. profile →
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

2015 698 citations Susanne Stowasser, Martin Kolb et al. European Respiratory Journal profile →
Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis

2001 623 citations Martin Kolb, Peter J. Margetts et al. profile →
An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis

2017 280 citations Gísli Jenkins, Martin Kolb et al. American Journal of Respiratory Cell and Molecular Biology profile →
Idiopathic pulmonary fibrosis: state of the art for 2023

2023 175 citations Anna J. Podolanczuk, Luca Richeldi et al. European Respiratory Journal profile →

Peers

Countries citing papers authored by Martin Kolb

Since Specialization

Citations

This map shows the geographic impact of Martin Kolb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kolb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kolb more than expected).

Fields of papers citing papers by Martin Kolb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Kolb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kolb. The network helps show where Martin Kolb may publish in the future.

Co-authorship network of co-authors of Martin Kolb

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Kolb. A scholar is included among the top collaborators of Martin Kolb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Kolb. Martin Kolb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modulating pro-fibrotic macrophages using yeast beta-glucan microparticles prepared by Pressurized Gas eXpanded liquid (PGX) Technology® 2024 ·Biomaterials ·(unknown), (unknown), (unknown), (unknown), (unknown), Megan Vierhout, Emily Wong, (unknown), (unknown), (unknown), (unknown), Martin Kolb, Kjetil Ask, Todd Hoare	2
2	Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study 2024 ·Respiratory Research ·Athol U. Wells, Simon Walsh, Ayodeji Adegunsoye, Vincent Cottin, Sonye K. Danoff, Anand Devaraj, Kevin R. Flaherty, Peter M. George, Kerri A. Johannson, Martin Kolb, Yasuhiro Kondoh, Andrew G. Nicholson, Sara Tomassetti, Elizabeth R. Volkmann, Kevin K. Brown	3
3	Characteristics of pulse oximetry and arterial blood gas in patients with fibrotic interstitial lung disease 2024 ·BMJ Open Respiratory Research ·M Donaldson, (unknown), Deborah Assayag, (unknown), Jolene H. Fisher, Kerri A. Johannson, Martin Kolb, (unknown), H. Manganas, Veronica Marcoux, (unknown), Julie Morisset, (unknown), Christopher J. Ryerson	0
4	The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions 2024 ·American Journal of Respiratory and Critical Care Medicine ·Jürgen Behr, Margaret L. Salisbury, Simon Walsh, Anna J. Podolanczuk, Lida P. Hariri, Gary M. Hunninghake, Martin Kolb, Christopher J. Ryerson, Vincent Cottin, Mary Beth Beasley, Tamera J. Corte, Allan R. Glanville, Ayodeji Adegunsoye, Cory M. Hogaboam, Wim Wuyts, Imre Noth, Justin M. Oldham, Luca Richeldi, Ganesh Raghu, Athol U. Wells	11
5	Defective mesenchymal Bmpr1a-mediated BMP signaling causes congenital pulmonary cysts 2023 ·eLife ·Yongfeng Luo, (unknown), Joanne Chiu, Hui Chen, Hongjun Wang, Matthew E. Thornton, Brendan H. Grubbs, Martin Kolb, Michael S. Parmacek, Yuji Mishina, Wei Shi	1
6	Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial 2023 ·Respirology ·Yoshikazu Inoue, Athol U. Wells, Jin Woo Song, Zuojun Xu, Hideya Kitamura, Takafumi Suda, Masaki Okamoto, Heiko Müller, Carl Coeck, Klaus Röhr, Martin Kolb, Kevin K. Brown	4
7	Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease 2022 ·Respirology ·Boyang Zheng, (unknown), Nathan Hambly, Kerri A. Johannson, Deborah Assayag, Jolene H. Fisher, H. Manganas, Veronica Marcoux, Nasreen Khalil, Martin Kolb, Christopher J. Ryerson, (unknown)	2
8	Treatment Initiation in Patients with Interstitial Lung Disease in Canada 2021 ·Annals of the American Thoracic Society ·Deborah Assayag, (unknown), Kerri A. Johannson, Charlene D. Fell, Martin Kolb, Gerard Cox, Nathan Hambly, H. Manganas, Julie Morisset, Jolene H. Fisher, Shane Shapera, Andrea S. Gershon, Teresa To, Mohsen Sadatsafavi, Pearce Wilcox, Andrew J. Halayko, Nasreen Khalil, Christopher J. Ryerson	7
9	Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study 2021 ·Respirology ·Mohammed A. Farooqi, Sachi O’Hoski, Sarah Goodwin, (unknown), (unknown), Gerard Cox, Joshua Wald, Christopher J. Ryerson, Marla Beauchamp, Nathan Hambly, Martin Kolb	17
10	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial 2021 ·European Respiratory Journal ·Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Luca Richeldi, Simon Walsh, Martin Kolb, Dirk Koschel, Teng Moua, Susanne Stowasser, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Kevin K. Brown	65
11	Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications 2021 ·Expert Opinion on Therapeutic Targets ·Toyoshi Yanagihara, Ciaran Scallan, Kjetil Ask, Martin Kolb	7
12	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement 2020 ·Canadian Journal of Respiratory Critical Care and Sleep Medicine ·Jolene H. Fisher, Kerri A. Johannson, Deborah Assayag, Julie Morisset, (unknown), H. Manganas, Shane Shapera, Charlene D. Fell, Christopher J. Ryerson, Martin Kolb	10
13	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases breakdown → 2019 ·New England Journal of Medicine ·Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Simon Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser, Carl Coeck, Emmanuelle Clerisme-Beaty, (unknown), Manuel Quaresma, Thomas Haeufel, Rainer-Georg Goeldner, Rozsa Schlenker‐Herceg, Kevin K. Brown	1333
14	IL‐6 mediates ER expansion during hyperpolarization of alternatively activated macrophages 2018 ·Immunology and Cell Biology ·Ehab Ayaub, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Chandak Upagupta, (unknown), Anna Dvorkin‐Gheva, James S. Murphy, Philipp Kolb, Šárka Lhoták, Jeffrey G. Dickhout, (unknown), Martin Kolb, Carl D. Richards, Kjetil Ask	21
15	Lysyl Oxidase–Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-β1–induced Pulmonary Fibrosis 2017 ·American Journal of Respiratory Cell and Molecular Biology ·Pierre‐Simon Bellaye, Chiko Shimbori, Chandak Upagupta, Seidai Sato, Wei Shi, Jack Gauldie, Kjetil Ask, Martin Kolb	49
16	Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis 2017 ·Scientific Reports ·Ehab Ayaub, (unknown), (unknown), Fernando Botelho, Martin Kolb, Carl D. Richards, Kjetil Ask	83
17	Stretch-induced Activation of Transforming Growth Factor-β1 in Pulmonary Fibrosis 2016 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Chiko Shimbori, Pierre‐Simon Bellaye, Mark D. Inman, (unknown), (unknown), Gísli Jenkins, Jack Gauldie, Kjetil Ask, Martin Kolb	148
18	Fibroblast growth factor‐1 attenuates TGF‐β1‐induced lung fibrosis 2016 ·The Journal of Pathology ·Chiko Shimbori, Pierre‐Simon Bellaye, (unknown), Jack Gauldie, Kjetil Ask, Carlos Ramos, Carina Becerril, Annie Pardo, Moisés Selman, Martin Kolb	79
19	Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor 2004 ·American Journal of Respiratory and Critical Care Medicine ·Philippe Bonniaud, Peter J. Margetts, Martin Kolb, (unknown), Ann M. Kapoun, Debby Damm, Alison Murphy, Sarvajit Chakravarty, Sundeep Dugar, Linda S. Higgins, Andrew A. Protter, Jack Gauldie	210
20	Newborn hearing testing at Wisconsin hospitals: a review of the need for universal screening. 2000 ·PubMed ·John Meurer, Michael J. Malloy, Martin Kolb, (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact